Key opinion leaders open a discussion surrounding CLL and SLL, and describing unique characteristics of each disease state.
Optimizing BTK Inhibitors in CLL and SLL
Clinical manifestations and impact on patient quality of life amid diagnosis and management of CLL and SLL are discussed.
A panel of experts explore current treatment strategies in CLL and SLL management.
Deborah Stephens, DO, shares unmet needs in the current treatment landscape of CLL and SLL.
Dr Haumschild drives a discussion surrounding the role of bruton kinase inhibitors for treating CLL and SLL.
Safety considerations for BTKi use in CLL and SLL treatment are highlighted.
Medical experts illustrate the impact of combination therapy for treatment of CLL and SLL.
Dr Haumschild drives a discussion surrounding the role of bruton kinase inhibitors for treating CLL and SLL.
Experts evaluate the financial impact experience by patients receiving BTK inhibitor therapy.
The criticality of patient education in BTKi use and its impact on treatment adherence is discussed.
The panelists provide perspectives on critical aspects of the CLL and SLL treatment landscape.
Medical experts provide their final thoughts regarding key treatment considerations for CLL and SLL.
Advertisement
Advertisement
Trending on AJMC
1
EHA 2026 Late Breakers Deliver Practice-Shifting Phase 3 Data and Novel CAR T Approaches Across Hematology
2
MRD-Guided CLL Treatment Duration: Personalization or Malpractice?
3
Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD
4
Global Hematology Trials Ensure Research Stays Applicable, Flexible, Patient-Centered
5